Digi International to Deliver Comprehensive 5G-Enabled Wireless Networking Solutions for Enterprise and Transportation Markets
28.4.2021 15:00:00 EEST | Business Wire | Press release
Digi International (NASDAQ: DGII) (www.digi.com), a leading global provider of Internet of Things (IoT) connectivity products and services, announces its comprehensive new 5G solution, which combines Digi Remote Manager ® with its versatile new 5G routers, which are sampling now and will become commercially available in July. Together, Digi's 5G software and hardware provide best-in-class performance for high-speed wired and wireless connectivity to advance mission-critical networks.
Digi Remote Manager serves as the command center of an intelligent network, providing centralized control of device configuration and management, security, edge intelligence, and day-to-day network management. As a cloud-based offering, Digi Remote Manager makes it easy to add, activate and safeguard new devices, including Digi’s new EX50 5G all-in-one enterprise router and TX64 5G high-end transportation router -- all from a desktop, tablet or phone.
The new-to-market Digi EX50 offers a high-performance enterprise solution for the fixed wireless access (FWA) market. In a series of firsts, the Digi EX50 will be the first Digi 5G router; the first enterprise-grade, work-from-anywhere solution; the first Digi router to support enterprise grade Wi-Fi 6; and the first Digi router to support PoE+.
“Digi Remote Manager, now coupled with our newest 5G routers, demonstrates our strategy to meet the growing demand for 5G solutions. We’ve built a 5G offering to address customers’ concerns that networking investments today might be obsolete tomorrow,” said Mike Ueland, President of IoT Products & Services. “Digi continues to make significant investments in leading-edge technology so that our customers have the best available choices regardless of location.”
In addition to supporting higher speeds, Digi’s 5G-enabled solutions will reduce latency, enable real-time analytics at the edge, and enable customers to build private 5G networks. The combination of 5G with Wi-Fi 6 and WPA3 also brings benefit to any application that requires secure Wi-Fi for many clients or bandwidth-hungry devices. Digi EX50’s latest generation Wi-Fi 6 radios operate simultaneously on 2.4 and 5 GHz bands and offer higher speed, capacity, and range than previous Wi-Fi products.
Ueland added, “Digi’s approach with customers is grounded in the reality that today’s project may be best-served with 4G solutions that provide a seamless transition to 5G when those networks are more widely deployed. As an industry leader, enhancing what’s available in the present while also delivering 5G solutions for the future, is standard operating procedure at Digi. It’s our trusted partner approach and commitment to satisfying and safeguarding customers that sets us apart from the competition -- that’s a Digi promise.”
For more information about Digi, visit: www.digi.com
About Digi International
Digi International (NASDAQ: DGII) is a leading global provider of IoT connectivity products, services, and solutions. The company helps customers create next-generation connected products, and deploy and manage critical communications infrastructures in demanding environments with high levels of security and reliability. Founded in 1985, Digi has helped organizations connect more than 100 million things – and counting. For more information, visit Digi's website at www.digi.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210428005129/en/
Contact information
Peter Ramsay/Lora Wilson
Global Results Communications
digi@globalresultspr.com
949.307.5908
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
